How does the presence of CNS disease affect your choice of first line therapy in Her2+ gastric adenocarcinoma?

Would you consider using Enhertu based on the Destiny-Gastric03 data?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

What is the optimal systemic therapy for metastatic Gastric Adenocarcinoma with Enteroblastic Differentiation (GAED)?

What are your top takeaways in GI Cancers from ESMO 2025?

How, if at all, will you incorporate durvalumab + FLOT in patients with HER2+ resectable gastric/GEJ adenocarcinoma?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.